Royalty Pharma plc RPRX
66.40 USD -0.12 (-0.18%)
At closeNov 3, 2026, 6:30 PM EST
66.40 0.00 0.00%
After hours · Nov 3, 6:30 PM ET
66.12 Day range 67.44
36.03 52-week range 67.71
- YTD
- +71.84%
- 1 year
- +78.02%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 65.38 -1.5% downside
Now 66.40
- Target (low)
- 61.00
- Target (mean)
- 65.38
- Target (high)
- 70.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.18 | 1.15 – 1.22 | 1.17 | +0.6% | 884.84M | +8.7% | 6 |
| Next quarter | 1.52 | 1.39 – 1.63 | 1.47 | +3.8% | 941.99M | +7.8% | 5 |
| Current year | 5.32 | 5.17 – 5.44 | 4.83 | +10.2% | 3.51B | +7.7% | 6 |
| Next year | 5.81 | 5.31 – 6.23 | 5.32 | +9.2% | 3.82B | +9.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 7, 2026 | Citigroup | Maintained | Buy | Buy |
| May 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 21, 2026 | UBS | Maintained | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jan 30, 2026 | UBS | Upgrade | Neutral | Buy |
| Jan 27, 2026 | Citigroup | Maintained | Buy | Buy |
| Dec 11, 2025 | TD Cowen | Maintained | Buy | Buy |
| Oct 10, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 30, 2025 | Goldman Sachs | Initiated | — | Buy |
| Jul 22, 2025 | Citigroup | Maintained | Buy | Buy |
| Jul 10, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 25, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 14, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jun 3, 2024 | UBS | Downgrade | Buy | Neutral |
| Apr 12, 2024 | B of A Securities | Maintained | Buy | Buy |
| Feb 20, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 20, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Nov 9, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 11, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 9, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 11, 2023 | Morgan Stanley | Reiterated | Overweight | Overweight |
| May 10, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Apr 10, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Apr 6, 2023 | Tigress Financial | Reiterated | — | Buy |
| Feb 16, 2023 | UBS | Maintained | — | Buy |
